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Abstract
This study aimed to investigate the epidemiology of hepatitis C virus (HCV)
genotypes in the Middle East and North Africa (MENA) through an analytical and
quantitative meta‐regression methodology. For the most common genotypes 1, 3, and
4, country/subregion explained more than 77% of the variation in the distribution of
each genotype. Genotype 1 was common across MENA, and was more present in
high‐risk clinical populations than in the general population. Genotype 3 was much
more present in Afghanistan, Iran, and Pakistan than the rest of countries, and was
associated with transmission through injecting drug use. Genotype 4 was broadly
disseminated in Egypt in all populations, with overall limited presence elsewhere.
While genotype 2 was more present in high‐risk clinical populations and people who
inject drugs, most of the variation in its distribution remained unexplained.
Genotypes 5, 6, and 7 had low or no presence in MENA, limiting the epidemiological
inferences that could be drawn. To sum up, geography is the principal determinant of
HCV genotype distribution. Genotype 1 is associated with transmission through high‐
risk clinical procedures, while genotype 3 is associated with injecting drug use. These
findings demonstrate the power of such analytical approach, which if extended to
other regions and globally, can yield relevant epidemiological inferences.
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1 | INTRODUCTION
The hepatitis C virus (HCV) is a major global health challenge.1 An
estimated 20% of all individuals chronically infected with HCV are
residing in the Middle East and North Africa (MENA).2,3 Chronic HCV
infection leads to various morbidities, such as liver fibrosis, cirrhosis,
and cancer,4 all of which strains healthcare systems.5
HCV displays extensive genetic diversity and is categorized into
seven genotypes (numbered from 1 to 7).6 Although genotypes 1 and
3 are common worldwide,6 genotype distribution can vary from one
geographical area to another.6,7 Specific HCV genotypes have been
hypothesized to be associated with specific modes of acquisition, or
with specific populations.6-8 However, any specific genotype circulat-
ing within a specific population tends also to be reflective of the
circulating genotypes in the wider population of that country.7
Delineating the epidemiology of HCV genotypes is critical as it
can convey inferences about the modes of transmission and their
dynamics in a given population.6,9 Despite this, existing studies tend
to be descriptive and qualitative in nature.6-8 Against this back-
ground, we aimed to demonstrate, to our knowledge for the first
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time, an analytical and quantitative approach to investigate the
epidemiology of HCV genotypes, through meta‐regressions, as
applied to HCV genotype distribution in MENA. This study is part
of the MENA HCV Epidemiology Synthesis Project, an ongoing
endeavor to delineate HCV epidemiology and inform key public
health research, policy, and programming priorities in MENA.7,10-26
2 | METHODS
Studies reporting HCV genotype data were retrieved from the MENA
HCV Epidemiology Synthesis Project database,2 originally for an
earlier study of HCV genotypes in MENA.7 This comprehensive
database consists of several subdatabases on different HCV
epidemiological measures, and was populated through a series of
systematic reviews for HCV infection across MENA.10-17,26 The
reviews followed the same methodology, informed by the Cochrane
Collaboration handbook,27 and used the Preferred Reporting Items
for Systematic reviews and Meta‐analyses (PRISMA) guidelines28 to
report their findings.
In these reviews, genotype information were extracted from
individual studies to populate the HCV genotype subdatabase.
Participants with untypeable genotype were removed from the sample
size of the study. Participants with mixed genotypes contributed
separately to the quantification of each genotype. The population of
each study was classified into six risk categories based on the
exposure risk to HCV infection, as presented in Figure 1 and as
informed by existing literature29-31 and our earlier studies.10-17,26 A
total of 175 genotype studies on 15 960 participants were included.
Univariable and multivariable random effects meta‐regressions
were conducted for the proportion of each HCV genotype, based on
established statistical methodology,27 to assess the association
between genotype and each of country/subregion and population
classification. Variables with a likelihood ratio test P < .2 in the
univariable analysis qualified for inclusion in the multivariable analysis.
Relative risks and adjusted relative risks (ARRs) with a P value
between .05 and .10 in the multivariable model, for any association
between genotype and a given factor, indicated good evidence for the
association. P ≤ .05 indicated strong evidence for the association.
3 | RESULTS
The results of the meta‐regressions are shown in Table 1 with key
results described in the following subsections.
3.1 | Genotype 1
There was strong evidence for variation in genotype 1 distribution by
country/subregion, and good evidence for variation by population.
Relative to Egypt, all countries/subregions had much higher presence
of genotype 1, apart from Pakistan. Genotype 1 was also more present
in high‐risk clinical populations (ARR of 1.2 [95% confidence interval
[CI]:1.0‐1.5]) than in the general population. Country/subregion and
population explained the vast majority of the variation in genotype 1
distribution (84.4%), mostly through the country/subregion variable.
3.2 | Genotype 2
There was strong evidence for variation in genotype 2 distribution by
country/subregion and by population. Relative to Egypt, the Gulf,
Fertile Crescent, Maghreb, and Pakistan had higher presence of
genotype 2. Genotype 2 was also more present in high‐risk clinical
populations, populations at intermediate risk, and people who inject
drugs (PWID), relative to the general population. Country/subregion
and population explained only 28.8% of the variation in genotype 2
distribution, mostly through the country/subregion variable, with
most variation remaining unexplained.
3.3 | Genotype 3
There was strong evidence for variation in genotype 3 distribution by
country/subregion, and good evidence for variation by population.
Relative to Egypt, all countries/subregions had substantially higher
presence of genotype 3. This was particularly so for Afghanistan, Iran,
and Pakistan, that had much higher presence of this genotype.
Genotype 3 was also more present in PWID (ARR of 1.7 [95% CI: 1.0‐
3.0]) than in the general population. Country/subregion and popula-
tion explained the vast majority of the variation in genotype 3
distribution (77.9%), mostly through the country/subregion variable.
A sensitivity analysis (Table S1) was performed in which the
meta‐regressions were performed excluding countries in which
genotype 3 was the most dominant genotype (Afghanistan and
Pakistan but not Iran7). The analysis was conducted to assess the
purported global association between this genotype and PWID.6 It
F IGURE 1 Population classification into categories by risk of
exposures to hepatitis C virus (HCV) infection
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was found that there is indeed strong evidence for an association
between this genotype and PWID (ARR of 2.7 [95% CI: 1.2‐5.8]).
The sensitivity analysis also confirmed the strong evidence for
variation by country/subregion—country/subregion and population
explained the majority of the variation (66.4%), mostly through the
country/subregion variable.
3.4 | Genotype 4
There was strong evidence for variation in genotype 4 distribution by
country/subregion, with most countries having substantially lower
(Gulf and Fertile Crescent), or much lower (Afghanistan, Iran,
Maghreb, and Pakistan) presence of this genotype compared with
Egypt. No significant evidence was found for variation in genotype 4
distribution by population, probably reflecting the broadly dissemi-
nated nature of the genotype 4 epidemic in Egypt.7,10 Country/
subregion and population explained the vast majority of the variation
in genotype 4 distribution (90.3%), nearly all of which through the
country/subregion variable.
3.5 | Genotype 5
Unlike the other genotypes, most of the variation in the distribution
of genotype 5 was explained by the population variable, rather than
the country/subregion variable. Paradoxically also, compared with
the general population, there was strong evidence for higher
presence of this genotype in special clinical populations, but lower
presence in high‐risk clinical populations. Moreover, of all countries/
subregions, only the Fertile Crescent had higher presence of
genotype 5 relative to Egypt. Population and country/subregion
explained 57.3% of the variation in genotype 5 distribution. These
results, which are epidemiologically not easy to interpret, could be
an artifact of the very low presence of this genotype in the MENA
region.7 Genotype 5 was identified in only 3.9% of all genotype
studies, with only 0.1% of infections being with this genotype.
3.6 | Genotype 6 and genotype 7
There were too few studies in which genotype 6 was identified
(1.7%), resulting in very broad confidence intervals of limited
implications, thus no analyses are reported for this genotype. No
study identified the presence of genotype 7 in MENA.
4 | DISCUSSION
We used a quantitative analytical approach to investigate epidemio-
logical associations for HCV genotypes, with application to the
MENA region. The utility of this approach was demonstrated—the
study yielded estimates for the differences in genotype distributions
by country/subregion and by population type. Overall, country/
subregion explained most of the variation, highlighting geography as
the principal determinant of genotype distribution. Interestingly, we
found evidence for an association between genotype 1 and high‐risk
clinical populations, possibly explaining, with the global presence of
these populations, the common presence of this genotype across
countries.6 This finding also supports existing literature suggesting
such an association.6 We further found an association between
genotype 3 and PWID, thereby supporting an apparently global role
for this genotype in HCV transmission through injecting drug use.6
While these findings were generated for MENA, they may reflect
generic results of global relevance.
Genotype epidemiology in the region may have been influenced
by several factors. The importation of contaminated blood products,
before the onset of blood screening, primarily from Western
countries, has been linked to a fraction of reported HIV cases,32,33
and presumably helped disseminate HCV genotype 1 across the
region.6 Genotype 1 was ubiquitous across most countries and
subregions of MENA, which may also be attributed to population
movement links to countries outside of MENA, as genotype 1 is the
most common genotype globally.6,30 For example, the presence of
genotype 1 was highest in the Maghreb subregion, almost 11‐fold
higher than in Egypt, a subregion which has strong migration links
with western and southern Europe.34,35
The emerging HIV epidemics among PWID in MENA, and
specifically in Afghanistan, Iran, and Pakistan, have been linked to
overlapping injecting networks across these countries.36-38 This may
have (partially) contributed to the relatively larger presence of
genotype 3 among PWID in these countries. A strong presence of
genotype 4 was found in Egypt. Phylogenetic evidence has shown
that genotype 4 in this country originated from central Africa,39 and
circulated endemically until the mass expansion of the HCV epidemic
through the parenteral antischistosomal therapy (PAT) campaigns
and other healthcare practices.10,11,39-43 Genotype 4 was also found
to be present in countries that host large migrant labor populations
from Egypt,44 such as in countries of the Fertile Crescent13 and
Gulf26 subregions of MENA.7,18
This study had limitations. HCV genotype data were not available
for several countries. The number of studies also varied by
population type and country/subregion, and the sample size of
genotyped individuals was small for a number of studies—we may not
have had sufficient statistical power to discern specific associations.
This may explain the lack of a clear interpretation/identification of
epidemiological associations for genotype 5. We assessed associa-
tions for specific key factors that were available in extracted data,
but we were unable to assess the role of a broader set of factors. This
may clarify why most variation in genotype 2 distribution remained
unexplained. Despite these limitations, we were able to utilize a
breadth of genotype data that was systematically gathered and that
allowed us to conduct such analysis, yielding relevant inferences
about genotype distribution and HCV transmission dynamics.
In conclusion, geography appears to be the principal determinant
of HCV genotype distribution. Genotype 1 is associated with
transmission through high‐risk clinical procedures, such as blood
transfusions, hemodialysis, and medical injections; while genotype 3 is
associated with transmission through injecting drug use. These findings
6 | MAHMUD ET AL.
demonstrate the power of such an analytical approach, which if
extended to other regions and globally, may yield relevant epidemio-
logical inferences that can inform control and treatment programs.
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